
 200 ANNUAL GOVERNANCE STATEMENT

201

 202 INTRODUCTION AND CONTEXT

203 NHS Dorset Clinical Commissioning Group is a body corporate established by NHS England on 1 April
204 2013 under the National Health Service Act 2006 (as amended).

205 The Clinical Commissioning Group's (CCG) statutory functions are set out under the National Health
206 Service Act 2006 (as amended). The CCG's general function is arranging the provision of services for
207 persons for the purposes of the health service in England. The CCG is, in particular, required to
208 arrange for the provision of certain health services to such extent as it considers necessary to meet
209 the reasonable requirements of its local population.

210 As at 1 April 2016, the clinical commissioning group is not subject to any directions from NHS
211 England issued under Section 14Z21 of the National Health Service Act 2006.

 212 SCOPE OF RESPONSIBILITY

213 As Accountable Officer, I have responsibility for maintaining a sound system of internal control that
214 supports the achievement of the clinical commissioning group's policies, aims and objectives, whilst
215 safeguarding the public funds and assets for which I am personally responsible, in accordance with
216 the responsibilities assigned to me in Managing Public Money. I also acknowledge my responsibilities
217 as set out under the National Health Service Act 2006 (as amended) and in my Clinical
218 Commissioning Group Accountable Officer Appointment Letter.

219 I am responsible for ensuring that the clinical commissioning group is administered prudently and
220 economically and that resources are applied efficiently and effectively, safeguarding financial
221 propriety and regularity. I also have responsibility for reviewing the effectiveness of the system of
222 internal control within the clinical commissioning group as set out in this governance statement.

 223 GOVERNANCE ARRANGEMENTS AND EFFECTIVENESS

224 The main function of the Governing Body is to ensure that the group has made appropriate
225 arrangements for ensuring that it exercises its functions effectively, efficiently and economically and
226 complies with such generally accepted principles of good governance as are relevant to it. This is in
227 line with the National Health Service Act 2006 (as amended), at paragraph 14L(2)(b).

228 The Membership has retained the power to make changes to its core constitution but has delegated
229 the majority of the decision making functions to the CCG's Governing Body. The Governing Body
230 has, in turn, delegated some decision making to the organisation's committees. Further information
231 relating to the delegated responsibility to each of the committees is detailed in the Annual Report
232 and Accounts 2016/17 and terms of reference (see pages 52 to 54).

233

234 COMPLIANCE WITH THE UK CORPORATE GOVERNANCE CODE

235 We are not required to comply with the UK Corporate Governance Code. However, we have
236 reported on our corporate governance arrangements by drawing upon best practice available,
237 including those aspects of the UK Corporate Governance Code we consider to be relevant to the
238 Clinical Commissioning Group and best practice.

239 From 1 April 2016 and up to the date of signing this statement, the CCG has complied with the
240 provisions set out in the NHS Clinical Commissioning Group's Code of Governance and applied the
241 principles of the Code.

242 New governance structures have been introduced which take into account the transformation work
243 streams under the Sustainability and Transformation plans, which will be instrumental in the design,
244 engagement, commissioning and delivery of new services, including services impacting on primary
245 care providers.

246 'Declarations of interest' is a standing agenda item at all CCG meetings. All declarations are
247 recorded and, where any conflict of interest is identified, appropriate action is taken. (See page 55)

248 Under the comply or explain principle, the CCG does not comply with Statutory Guidance issued
249 regarding conflicts of interest and voting rights in respect of GPs on the Primary Care Commissioning
250 Committee. We believe that having two classes of members, one with and one without voting rights
251 would be detrimental to good governance. We have instead introduced a presumption that GPs will
252 be conflicted from voting or participation in discussion on papers presented to the Committee unless
253 they declare that they are not conflicted.

254 DISCHARGE OF STATUTORY FUNCTION

255 I can confirm that the correct arrangements are in place for the discharge of statutory functions.

256 During establishment, the arrangements put in place by the CCG and explained within the UK
257 Corporate Governance Code were developed with extensive expert external legal input to ensure
258 compliance with all the relevant legislation. The legal advice also informed the matters reserved for
259 Membership Body and Governing Body decision and the scheme of delegation.

260 In light of recommendations of the 1983 Harris Review, the clinical commissioning group has
261 reviewed all of the statutory duties and powers conferred on it by the National Health Service Act
262 2006 (as amended) and other associated legislative and regulations. As a result, I can confirm that
263 the clinical commissioning group is clear about the legislative requirements associated with each of
264 the statutory functions for which it is responsible, including any restrictions on delegation of those
265 functions.

266 Responsibility for each duty and power has been clearly allocated to a lead Director. Directorates
267 have confirmed that their structures provide the necessary capability and capacity to undertake all
268 of the clinical commissioning group's statutory duties.

269 RISK MANAGEMENT ARRANGEMENTS AND EFFECTIVENESS

270 To enable the effective use of Governing Body time the CCG's risk appetite is being further refined to
 271 enable the Governing Body to consider an exception based reporting the decisions, thereby
 272 permitting the Governing Body to focus on critical issues.

273 Every activity that the CCG undertakes or commissions others to undertake on its behalf, brings with
 274 it an element of risk that has the potential to threaten or prevent the organisation achieving its
 275 strategic objectives. Unmanaged risk can affect people, assets, the organisation and reputation and
 276 ultimately be of detriment to the population the CCG serves.

277 The process of appropriately managing identified risk helps the CCG achieve agreed standards,
 278 reduce overall costs and maintain and enhance the standard of service provided.

279 The CCG is not aiming to create a risk-free environment, but rather one in which risk is considered as
 280 a matter of course and appropriately identified, controlled and managed.

281 In order to achieve this aim, risk management must be part of the culture of the CCG and a primary
 282 concern of all staff and stakeholders.

283 A Risk Management Framework was approved and endorsed by the shadow Governing Body in
 284 December 2012 ready for use in April 2013 to reflect the CCG's risk management requirements; the
 285 Framework was been updated and approved by the Directors in May 2015, with a review date of
 286 May 2017.

287 The Risk Management Framework:

- 288 • standardises and clarifies the terminology of risk management;
- 289 • sets out the organisation's objective to identify, treat and mitigate risk;
- 290 • explains the roles and responsibilities within the CCG relating to risk;
- 291 • defines the role and objectives of the CCG's committees and groups;
- 292 • clearly explains the tools (Corporate Risk Register and Governing Body Assurance Framework)
 293 used by the CCG to document and manage risks to the organisation, detailing the clear,
 294 consistent and effective risk scoring systems used;
- 295 • details how the organisation has a clear view of the risks affecting each area of its activity, how
 296 the risks are being managed and their potential impact on the organisational objectives;
- 297 • assures the public, patients and their carers and representatives, staff and partner organisations
 298 that the CCG is committed to managing risk appropriately.

299 In relation to risk management the Governing Body membership and executive team are responsible
 300 for:

- 301 • articulating the organisation's strategic objectives;
- 302 • identifying risks to the achievement of its strategic objectives;
- 303 • protecting the reputation of the CCG; providing leadership, active involvement and support for
 304 risk management;
- 305 • determining the risk appetite for the CCG;
- 306 • ensuring the approach to risk management is consistently applied;
- 307 • ensuring that there is a structure in place for the effective management of risk throughout the
 308 CCG and that this structure is consistently applied;

ACCOUNTABILITY REPORT

- 309 • monitoring these processes on an on-going basis via the Governing Body Assurance Framework
310 and Corporate Risk Register;
311 • reviewing and approving the Risk Management Framework on a biennial basis.

312 The CCG ensures that risk management is embedded in all aspects of the work of the organisation.
313 Examples include:

- 314 • **Equality Impact Assessments:** The CCG is committed to ensuring a reduction in health
315 inequalities and places the needs of Dorset communities at the heart of all commissioning
316 functions. 'Equality analysis' is undertaken when commissioning services, making changes to
317 services, using information within services and within the policies that are used.
318 Additionally, the CCG publishes an annual 'Equality and Diversity report' which
319 acknowledges the organisation's successes in relation to equality and diversity, as well as
320 making recommendations for improvement;
321 • **Incident Reporting:** Incident and serious incident reporting is openly encouraged from all
322 staff, GP practices and the provider organisations that are commissioned by the CCG. This
323 information is analysed and used to identify any risks which may impact in the business of
324 the CCG.

325 The CCG is committed to ensuring that public stakeholders are involved in managing risks which
326 impact on them. Examples include:

- 327 • lay representatives regularly attend the Governing Body, the Quality Group, Transformation
328 Quality Assurance Group and Audit and Quality Committee to ensure there is a voice for
329 patients and the public;
330 • information on "the need to change" in Dorset is being widely communicated on an on-
331 going basis to the public and other stakeholders – explaining why the NHS in Dorset needs to
332 change, what is being done and how people can be involved and have their say. This is
333 being communicated in accessible formats at public events, through presentations and Q&A
334 sessions, through newsletters, circulation of an information film etc;
335 • patient and carer representatives are invited to take part in task and finish groups and
336 workshops hosted by the CCG's Clinical Delivery Groups, bringing people into the room so
337 that local care pathways can be designed 'with' them rather than 'for' them;
338 • the CCG has a Patient (Carer) Public Engagement Group comprising about 20 people with
339 lived experience across Dorset's geography, demography and diversity – who meet on a
340 monthly basis and act as a critical friend – providing advice and feedback on proposed
341 service changes/developments.

CAPACITY TO HANDLE RISK

343 The framework provides assurance to the Governing Body of the controls that are in place to
344 mitigate the key risks that could impact on the CCG's delivery of its strategic objectives. Key controls
345 for which assurance cannot be fully detailed are highlighted in blue on the framework, with an
346 explanation of the work in progress to achieve assurance. Monthly updates are provided to the
347 Executive Team of the progress against achieving full assurance, with formal reports submitted to
348 every Governing Body and Audit and Quality Committee meeting.

349 This pro-active method of managing risk is a preventative approach to limit the risk exposure to the
350 organisation.

351 The **Corporate Risk Register** is a risk management tool which acts as a central repository for all
 352 current risks identified by the organisation. All risks are recorded and managed via the Ulysses
 353 software 'Safeguard Risk Management System' and are mapped (where applicable) to the strategic
 354 objectives of the CCG.

355 The CCG also actively deters risks through the adoption of robust counter-fraud methodology. All
 356 clinical and non-clinical staff receives training on the identification of fraud within the CCG. In
 357 addition, the CCG have a contract with Tiaa (as from 1.7.16) and previously with Secure (Fraud and
 358 Security Solutions) to provide counter fraud and security management services that have an annual
 359 work programme.

360 The CCG's Executive Lead for fraud and corruption is the Chief Finance Officer, who is responsible for
 361 authorising investigations, including the arrest, interviewing and prosecution of subjects and the
 362 recovery or write-off of any sums lost to fraud.

363 The CCG is able to assure itself of the validity of the Annual Governance Statement in a number of
 364 ways. These are:

- 365 • adherence to the Risk Management Framework;
- 366 • adherence to the CCG committee structure, Committee Terms of Reference and reporting
 367 framework;
- 368 • scrutiny of the draft Annual Governance Statement (this document) by members of the Audit
 369 and Quality Committee prior to submission and sign off at the special meeting for closure of
 370 finances in May 2017.

371 Leadership for the risk management process within the CCG is provided via the Governing Body, with
 372 responsibility delegated to the Audit and Quality Committee. The organisational structure has been
 373 established in order to assist with this process and is described in the following paragraphs.

374 All Directors are responsible for compliance with the Risk Management Framework to ensure that
 375 remedial actions are identified and taken wherever key risks are identified within their area of
 376 responsibility.

377 The Director of Quality and Nursing is the designated lead for risk and patient safety within the CCG,
 378 and is responsible for ensuring that the Risk Management Framework is implemented and evaluated
 379 effectively.

380 All Directors, Deputy Directors and Managers have delegated responsibility and authority with
 381 regard to the management of risk within their specific areas of work, including compliance with the
 382 Risk Management Framework and for ensuring that remedial action is taken wherever key risks are
 383 identified within their area of responsibility, including:

- 384 • the reporting of adverse incidents, together with actions to prevent or minimise a reoccurrence;
- 385 • identifying and adding risks to the Corporate Risk Register in a timely manner;
- 386 • coordinating the application of resources to minimise, manage and control the likelihood
 387 and/or impact of the risk;
- 388 • undertaking risk assessments and actions implemented;
- 389 • ensuring staff undertake mandatory and statutory training.

390

391 The Head of Patient Safety and Risk, supported by the Patient Safety and Risk Manager has
392 delegated responsibility for:

- 393 • co-ordinating and managing activities relating to clinical, corporate and financial risks for the
394 CCG;
- 395 • monitoring risk management and patient safety within commissioned and corporate services
396 for the CCG;
- 397 • maintaining the Corporate Risk Register and Governing Body Assurance Framework through
398 engagement with the Directors and Directorate Risk Leads;
- 399 • the management of all Serious Incidents Requiring Investigation and Adverse Incidents.

400 The Patient Safety and Risk team within the CCG supports the consistent identification, assessment
401 and management of risk across the organisation and, as a team, are central to the dissemination and
402 application of best practice. Additionally the team administers the key administration and system
403 processes and acts as a central resource and advisory function in relation to risk and risk
404 management.

405 Plans are in place to enhance the risk training available to new and existing CCG employees through
406 the enhancement of key training and education programmes to ensure all staff learn through good
407 practice.

408 The cumulative contribution of the above mechanisms assists in the assurance of commissioning
409 services that ensure patient safety is high profile.

410 RISK ASSESSMENT

411 The CCG has continued to develop and embed its approaches to risk management as set out in the
412 Annual Governance Statement (2015/16). The CCG views integrated risk management as a key
413 element in the successful delivery of its business and remains committed to ensuring staff
414 throughout the organisation are equipped to assess, manage, escalate and report risks.

415 The CCG has clear governance structures with delegation of responsibility clearly articulated in the
416 terms of reference for committees and groups (as described on pages 52 to 54). All committees
417 review their effectiveness annually and there are clear lines of reporting from all committees and
418 groups to the Governing Body. The Governing Body through reports and updates reviews the quality,
419 performance and financial stewardship of the organisation. Any risks identified relating to these
420 areas have been recorded in the Corporate Risk Register and/or the Governing Body Assurance
421 Framework.

422 The CCG operates a 'Declaration of Interest' register and this is checked regularly; potential conflicts
423 of interest are taken into account in all aspects of the CCGs business. Declarations of interest are
424 recorded at every formal committee and group meeting.

425 The CCG operates a Governing Body Assurance Framework and Corporate Risk Register that identify
426 the systems of internal control in place to efficiently, effectively and economically manage these
427 risks and provide assurance to the CCG and its organisation's stakeholders that these systems are
428 present.

429 All risks identified in the Corporate Risk Register require the formulation of an action plan. A
430 member of the Patient Safety and Risk team meets with risk leads on a monthly or quarterly basis
431 (dependant on risk level) to record progress against action plans and documents the effect these are

432 having on the residual risk score. All action plans are formally reported via the Corporate Risk
 433 Register. The document includes all risks that may impact on the achievement of the CCG's
 434 objectives.

435 The Governing Body receives regular assurance on the management of internal risks and assurance
 436 both directly via regular reports including the full Governing Body Assurance Framework and
 437 Corporate Risk Register and via assurance from the Audit and Quality Committee.

438 Risks are scored on a likelihood x consequence matrix to score the potential severity of a risk being
 439 realised. Risks scored above 15 are categorised as high risk.

440 Reports are also received on a monthly basis by Directors summarising the top risks to the
 441 organisation (those scoring over 15), new risks, closed risks and any other key risk issues. Directors
 442 also review the full Corporate Risk Register at every meeting.

443 During 2016/17 a process has been developed to ensure an operational risk log is maintained for
 444 each project. There is a clear route to escalate any of the risks identified on the log to the Corporate
 445 Risk Register.

446 Between 1 April 2016 and 31 March 2017, 25 risks were added to the Corporate Risk Register. Of
 447 these 25 risks, 10 have been closed within the year. Of the remaining 15 open risks 6 are assessed as
 448 high risk:

- 449 • three relate to primary care capacity;
- 450 • one relates to delays in initial health assessments for looked after children;
- 451 • one relates to extension of existing contract for urgent care service;
- 452 • one relates to funding for digitally transformed Dorset.

453 The outstanding risks in place on 31 March 2017 are carried over into the new financial year and will
 454 continue to be managed within the Risk Management Framework described within this statement.

455 The risk profile of the CCG is subject to on-going in-year revision. At the end of the 2016/17 financial
 456 year, there were 36 risks on the Corporate Risk Register.

457 As Accountable Officer I can confirm that there have been no significant lapses of protective
 458 security.

459 THE CLINICAL COMMISSIONING GROUP INTERNAL CONTROL FRAMEWORK

460 A system of internal control is the set of processes and procedures in place in the Clinical
 461 Commissioning Group to ensure it delivers its policies, aims and objectives. It is designed to identify
 462 and prioritise the risks, to evaluate the likelihood of those risks being realised and the impact should
 463 they be realised, and to manage them efficiently, effectively and economically.

464 The system of internal control allows risk to be managed to a reasonable level rather than
 465 eliminating all risk; it can therefore only provide reasonable and not absolute assurance of
 466 effectiveness.

467 The Corporate Risk Register has controls described for every risk entry. The controls are reviewed on
 468 a monthly or quarterly basis (depending on their risk level) along with progress for reducing the risk
 469 to ensure they are still effective.

470 The framework provides assurance to the Governing Body of the controls that are in place to
471 mitigate the key risks that could impact on the CCG’s delivery of its strategic objectives.

472 ANNUAL AUDIT OF CONFLICTS OF INTEREST MANAGEMENT

473 The revised statutory guidance on managing conflicts of interest for CCGs (published June 2016)
474 requires CCGs to undertake an annual internal audit of conflicts of interest management. To support
475 CCGs to undertake this task, NHS England has published a template audit framework.

476 The annual internal audit of conflicts of interest was carried out January/February 2017 and
477 supported an overall assurance assessment of ‘reasonable assurance’. Our level of compliance on
478 the five areas as set by NHS England were as follows:

- 479 • governance arrangements – fully compliant;
- 480 • declarations of interests and gifts and hospitality – partially compliant; as at 31 March 2017
481 there are 32 members of staff including temporary and bank staff and those on long-term sick
482 and maternity who have not completed a declaration. 9 paid GPs and 21 practices have not
483 completed a declaration;
- 484 • registers of interests, gifts and hospitality and procurement decisions – partially compliant;
- 485 • decision making processes and contract monitoring – fully compliant;
- 486 • reporting concerns and identifying and managing breaches/non-compliance – fully compliant.

487 DATA QUALITY

488 The data used by the Governing Body and delegated Committees/groups is obtained from various
489 sources of which all are national systems. The Provider data is quality assured through contract and
490 performance monitoring and against the Secondary Uses Service (SUS) quality dashboard.

491 INFORMATION GOVERNANCE

492 The NHS Information Governance Framework sets the processes and procedures by which the NHS
493 handles information about patients and employees, in particular personal identifiable information.
494 The NHS Information Governance Framework is supported by an information governance toolkit and
495 the annual submission process provides assurances to the clinical commissioning group, other
496 organisations and to individuals that personal information is dealt with legally, securely, efficiently
497 and effectively.

498 The CCG places high importance on ensuring there are robust Information Governance (IG) systems
499 and processes in place to manage data security risks and the protection of patient and corporate
500 information. Responsibility for IG rests with me, as Accountable Officer; I have delegated authority
501 to the Senior Information Risk Owner (SIRO), the Caldicott Guardian and the Information
502 Governance Group (IGG). A range of measures are used to manage and mitigate information risks,
503 including annual mandatory staff training, physical security, data encryption, access controls and
504 departmental spot checks.

505 The CCG’s IG status is regularly reviewed by the IGG which is a standing group that reports to the
506 governing body via the Audit and Quality Committee. Its purpose is to support and drive the
507 broader IG agenda and provide assurance to the Governing Body that effective IG best practice
508 mechanisms are in place. Risks to information, including data security, confidentiality, integrity and
509 availability, are managed and controlled via this group which meets bi-monthly.

510 The SIRO has responsibility for leading and implementing the IG risk assessment and management
 511 processes within the CCG in addition to advising the Governing Body on the effectiveness of
 512 information risk management throughout the CCG.

513 As part of the annual IG Toolkit submission a comprehensive assessment of information security is
 514 undertaken. Further assurance is provided from audit and other reviews. The effectiveness of these
 515 measures is reported to, and monitored by, the IGG. This includes details of any personal data
 516 related serious incidents, the CCG's annual IG toolkit score and reports of other IG incidents and
 517 audit reviews. Regular reports are received in relation to policies, the Caldicott risk register,
 518 transition and records management.

519 There is a staff handbook in place to ensure that staff are aware of their roles and responsibilities
 520 under IG and the Data Protection Act.

521 The CCG has self-assessed against the IG Toolkit and achieved the target of overall compliance of
 522 Level 2 and above, with some criteria achieving Level 3. There has been an audit conducted on the
 523 evidence used to support the submission. This has provided substantial assurance to the Governing
 524 Body that there is a sound system of control in place.

525 There are processes in place for incident reporting and investigation of serious incidents.
 526 Information risk assessment and management procedures have been established via the IGG, the
 527 SIRO and the Risk Management Team. Work continually takes place to ensure that these are
 528 embedded throughout the organisation. All incidents which have a data protection element are
 529 investigated with lessons learnt shared via the IG Group.

530 There has been no serious breach of the Data Protection Act (Level 2 reportable) in 2016/17 which
 531 required reporting to the Information Commissioners Office.

532 For further information on responding to Freedom of Information requests please see page 37 of the
 533 Annual Report and Accounts.

534 BUSINESS CRITICAL MODELS

535 As Accountable Officer I can confirm that there is an appropriate financial and business framework
 536 and environment in place to provide assurance of business critical models, in line with the
 537 recommendation from the MacPherson report. These are overseen by the Governing Body and Audit
 538 and Quality Committee. External assurance is received via external audit and quarterly assurance
 539 meetings with NHS England.

540 THIRD PARTY ASSURANCES

541 Dorset CCG seeks third party assurances when a provider enters a sub-contracting arrangement.
 542 The lead provider is then required to report on outcomes of the commissioned service including all
 543 aspects of the sub contracted element of the service.

544

545 CONTROL ISSUES

546 There were no significant control issues identified in 2016/17.

547 REVIEW OF ECONOMY, EFFICIENCY AND EFFECTIVENESS OF THE USE OF RESOURCES

548 There are procurement processes to which the CCG adheres. There is a scheme of delegation which
549 ensures that financial controls are in place across the organisation.

550 The roles of the accountable and delegated committees and groups are clearly articulated in pages
551 52 to 54 of this statement and the scheme of delegation has been reviewed, and approved, in year.

552 As detailed on page 67, the CCG also actively deters risk through the adoption of robust counter-
553 fraud methodology.

554 DELEGATION OF FUNCTIONS

555 It is implicit through the work of the Governing Body and delegated Committees that members have
556 clear responsibility for ensuring appropriate use of resources. Where there are concerns in relation
557 to budgetary management, these are clearly documented in the Corporate Risk Register including
558 those key financial risks relating to the CCG's commissioned Providers. During the course of 2016/17
559 there were three risks identified and recorded on the Corporate Risk Register relating to aspects of
560 financial risk.

561 Through the committee structure within Dorset CCG, regular reports are received on the
562 performance of contracted Providers. Areas of under and over performance are addressed through
563 contract meetings and reported through performance and quality papers to CCG groups and
564 committees.

565 The Audit and Quality Committee, under the scheme of delegation, monitor the financial
566 stewardship of the organisation via detailed reporting to every meeting and is responsible for
567 scrutinising and signing off the end of year financial accounts. At year end the CCG achieved the
568 control total that had been agreed with NHS England.

569 The Governing Body, Audit and Quality Committee, Quality Group and Director's Performance
570 meetings retain oversight of all risks including those deemed to be systematic and are responsible
571 for ensuring that relevant mitigating actions are undertaken. There have been no significant internal
572 control failures identified throughout the financial year 2016/17.

573 Internal Audit has found no significant lapses in financial control or use of resources in any of the
574 audits that have been undertaken in this financial year. With the exception of the South West 999
575 service, Dorset CCG does not contract any commissioning support services from an external
576 Provider.

577 COUNTER FRAUD ARRANGEMENTS

578 The CCG's Accountable Officer for fraud and corruption is the Chief Finance Officer, who is
579 responsible for authorising investigations, including the arrest, interviewing and prosecution of
580 subjects and the recovery or write-off of any sums lost to fraud.

581 The CCG has a nominated Local Counter Fraud Specialist (LCFS) who is responsible for the
 582 investigation of any allegations of fraud and corruption and for the delivery of a programme of
 583 proactive counter fraud work, as detailed in the annual work-plan approved by the Audit and Quality
 584 Committee. Where fraud is established or improvements to systems or processes identified, the
 585 LCFS will recommend appropriate action to the CCG.

586 The LCFS works closely with the Workforce Department when investigating cases involving members
 587 of staff and provides evidence to the CCG's investigating officer for disciplinary matters.

588 Monitoring of the Group's counter fraud arrangements is undertaken by the Audit and Quality
 589 Committee. The LCFS, who is responsible for the investigation of any allegations of fraud and
 590 corruption and for the delivery of a programme of proactive counter fraud work, attends each
 591 committee meeting to report progress against the agreed counter fraud work-plan and advise the
 592 outcome of any completed investigations or proactive exercises.

593 A Fraud Response Plan is in place which sets out these roles and responsibilities and the steps to be
 594 taken by the CCG if fraud is suspected. All staff are required to report any suspicions of fraud or
 595 corruption that they may have either to the LCFS or the Chief Finance Officer.

596 See page 86 for further information on fraud.

597 **HEAD OF INTERNAL AUDIT OPINION**

598 Following completion of the planned audit work for the financial year for the clinical commissioning
 599 group, the Head of Internal Audit issued an independent and objective opinion on the adequacy and
 600 effectiveness of the clinical commissioning groups system of risk management, governance and
 601 internal control. The Head of Internal Audit (HoIA) concluded that:

602 The purpose of my annual HoIA Opinion is to contribute to the assurances available to the
 603 Accountable Officer and the Governing Body which underpin the Governing Body's own assessment
 604 of the effectiveness of the organisation's system of internal control. This Opinion will in turn assist
 605 the Governing Body in the completion of its Annual Governance Statement (AGS).

606 Based on its draft accounts, the CCG achieved its revenue resource surplus (including the non-
 607 recurrent system risk reserve figure of £11.1m) of £28,805k at the year end from a revenue resource
 608 limit of £1,161,142k. Our opinion on the organisation's system of internal control has taken this
 609 factor into account.

610 My opinion is set out as follows:

- 611 1. Overall opinion;
- 612 2. Basis for the opinion; and
- 613 3. Commentary.

614

615 My overall opinion is that:

- 616 • My overall opinion is that **Reasonable** assurance can be given that there is a generally sound
 617 system of internal control, designed to meet the organisation's objectives, and that controls are
 618 generally being applied consistently. However, some weakness in the design and/or
 619 inconsistent application of controls, put the achievement of particular objectives at risk.

620

621 The basis for forming my opinion is as follows:

- 622 • an assessment of the design and operation of the underpinning Assurance Framework and
- 623 supporting processes; and
- 624 • an assessment of the range of individual opinions arising from risk-based audit assignments,
- 625 contained within internal audit risk-based plans that have been reported throughout the year.
- 626 This assessment has taken account of the relative materiality of these areas and management’s
- 627 progress in respect of addressing control weaknesses.

628 Additional areas of work that may support the opinion will be determined locally but are not
 629 required for Department of Health purposes, eg any reliance that is being placed upon Third Party
 630 Assurances.

631 During the year, Internal Audit issued the following audit reports:

632 **Table 19: Internal audit reports**

System	Type	Assurance Assessment
Individual Funding Requests	Assurance	Substantial
Safeguarding Adults	Assurance	Reasonable
Cyber Security	Assurance	Reasonable
Procurement	Assurance	Substantial
Governance arrangements over Primary Care	Assurance	Reasonable
Engagement with Public and Patients	Assurance	Reasonable
Clinical Delivery Groups	Assurance	Reasonable
Financial Systems	Compliance	Reasonable
Personal Health Budgets	Assurance	Reasonable
Contract Performance and Quality Monitoring of Providers	Assurance	Substantial
Conflicts of Interest	Assurance	Reasonable
Information Governance Toolkit	Assurance	Substantial
Sustainability and Transformation Plan production processes internally and with partners	Assurance	Substantial
Transformation Plans (Local ICS Vanguard)	Assurance	Substantial
Primary Care Commissioning (draft)	Assurance	Reasonable
Assurance Framework and Risk Management (draft)	Assurance	Reasonable

633 There have been no priority 1 audit recommendations raised during the year.

634 **REVIEW OF THE EFFECTIVENESS OF GOVERNANCE, RISK MANAGEMENT AND INTERNAL**
 635 **CONTROL**

636 My review of the effectiveness of the system of internal control is informed by the work of the
 637 internal auditors, executive managers and clinical leads within the clinical commissioning group who
 638 have responsibility for the development and maintenance of the internal control framework. I have
 639 drawn on performance information available to me. My review is also informed by comments made
 640 by the external auditors in their annual audit letter and other reports.

641 Our assurance framework provides me with evidence that the effectiveness of controls that manage
 642 risks to the clinical commissioning group achieving its principles objectives have been reviewed. I
 643 have been advised on the implication of the result of this review by:

- 644 • the work of the internal auditors;
 645 • Executive Directors, Senior Managers and Clinical Leads within the CCG who have responsibility
 646 for the development and maintenance of the internal control framework;
 647 • available performance information;
 648 • comments made by the external auditors in their annual audit letter and other reports.

649 The Governing Body Assurance Framework and Corporate Risk Register have been designed to
 650 provide me, as Accountable Officer, with sources of assurance which are evidence that the
 651 effectiveness of controls that manage risks to the CCG are achieving their principal objectives and
 652 are reviewed on an on-going basis as described on pages 60 to 63.

653 The Executive Directors within the CCG who have responsibility for the development and
 654 maintenance of the system of internal control provide me, as Accountable Officer, with assurance.

655 As Accountable Officer, I have received assurance of the effectiveness of the CCG's internal controls
 656 as discharged through the committees described in page 52 to 54. Plans are in place to address any
 657 areas of improvement identified; monitoring arrangements are in place to address these.

658 Pages 52 to 54 describe the process that has been applied in maintaining and reviewing the
 659 effectiveness of the system of internal control, including the role and outputs of the:

- 660 • Governing Body;
- 661 • Audit and Quality Committee;
- 662 • Clinical Commissioning Committee;
- 663 • Remuneration Committee;
- 664 • Primary Care Commissioning Committee;
- 665 • Quality Group;
- 666 • Information Governance group.
- 667 • Transformation Quality Assurance Group

668 Management has provided representation that the agreed actions which are identified at each of
 669 these meetings are being implemented in accordance with the timescales provided to address the
 670 findings raised.

671 **Conclusion**

672 I can confirm that no significant internal control issues have been identified.

673
 674
 675

676 *[Signature to be inserted]*

677

678 **Tim Goodson**
 679 **Accountable Officer**
 680 **Xx May 2017**

681

682

683